Literature DB >> 7585595

Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.

C W Choi1, L Lang, J T Lee, K O Webber, T M Yoo, H K Chang, N Le, E Jagoda, C H Paik, I Pastan.   

Abstract

We evaluated the biodistribution, pharmacokinetics, and generation of catabolites of an 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragment (dsFv) in tumor-bearing nude mice. This dsFv is genetically engineered from a murine monoclonal antibody that recognizes the alpha subunit of the interleukin 2 (IL-2 alpha) receptor. Labeling was performed with 18F using N-succinimidyl 4-([18F]fluoromethyl)benzoate or with 125I using the Iodo-Gen method. The immunoreactivities of the radiolabeled anti-Tac dsFv were > 82%. The biodistribution was evaluated (at 15, 45, and 90 min and 6 h) in athymic nude mice (approximately five/group) bearing s.c. tumor xenografts. Cell line A431 served as the IL-2 receptor-negative control tumor, whereas the ATAC4 cell line served as our IL-2 receptor-positive tumor. Animals received injections of 18F-labeled anti-Tac dsFv (0.7-1.4 megabecquerels/1.5-3 micrograms) and 125I-labeled anti-Tac dsFv (0.1-0.4 megabecquerels/0.9-1 microgram). Blood clearance for both preparations was rapid, with < 10% retained in the blood by 15 min. Maximum accumulation in ATAC4 tumors occurred between 45 and 90 min and peaked at a mean of 4.2% injected dose/g (18F) and 5.6% of injected dose/g (125I). At 6 h, the ATAC4 tumors contained 11 times more 18F and 3 times more 125I than did the A431 tumors. The ATAC4 tumor:blood ratios for the 18F and 125I were > 12:1 and > 1.4:1 at 6 h, respectively, whereas the ratios for the antigen-negative A431 tumor were less than 1. The kidneys were the major route of elimination. Catabolites appeared quickly and were identified as [125I]iodide and predominantly N-epsilon-[18F]4-fluoromethylbenzoyl(alpha-N-acetyl) lysine. This is the first study to evaluate the biodistribution of an 18F-labeled Fv fragment in vitro and in vivo. In vivo, the dsFv was taken up rapidly by the kidneys, producing lysine-containing catabolites for 18F-labeled dsFv and [125I]iodide for 125I-labeled dsFv.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585595

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging.

Authors:  Tove Olafsen; Shannon J Sirk; Sebastian Olma; Clifton K-F Shen; Anna M Wu
Journal:  Tumour Biol       Date:  2012-03-06

3.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.

Authors:  A M Wu; P J Yazaki; S w Tsai; K Nguyen; A L Anderson; D W McCarthy; M J Welch; J E Shively; L E Williams; A A Raubitschek; J Y Wong; T Toyokuni; M E Phelps; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Authors:  Elaine M Jagoda; Lixin Lang; Veerendra Bhadrasetty; Stephanie Histed; Mark Williams; Gabriela Kramer-Marek; Esther Mena; Lauren Rosenblum; Jan Marik; Jeff N Tinianow; Mark Merchant; Lawrence Szajek; Chang Paik; Fabiola Cecchi; Kristen Raffensperger; Joe-Marie Jose-Dizon; Donald P Bottaro; Peter Choyke
Journal:  J Nucl Med       Date:  2012-08-23       Impact factor: 10.057

5.  Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.

Authors:  H Kobayashi; B F Sun; E S Han; M K Kim; N Le; Q C Wang; D L Nelson; I Pastan; T A Waldmann; C H Paik; J A Carrasquillo
Journal:  Jpn J Cancer Res       Date:  1998-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.